Belgium· BE-AMP-SAM554853-00
Recarbrio 500 mg - 500 mg - 250 mg
A imipenem, cilastatin and relebactam product containing relebactam monohydrate, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Imipenem, cilastatin and relebactam is registered in 11 of 19 countries.
Countries holding a registration under ATC J01DH56 (imipenem, cilastatin and relebactam), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Imipenem, cilastatin and relebactam · ATC J01DH56
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Relebactam Monohydrate
- Manufacturer
- Merck Sharp & Dohme
- Country
- Belgium (BE)
- ATC code
- J01DH56
- ATC class
- Imipenem, cilastatin and relebactam
- Defined daily dose
- 2 g, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J01DH56
Imipenem, cilastatin and relebactam, as other registers publish it.
- NorwayRecarbrioMSD
- PolandRecarbrioMerck Sharp & Dohme B.V.
- IcelandRecarbrioMerck Sharp & Dohme B.V.*
- DenmarkRecarbrioMerck Sharp & Dohme B.V.
- NorwayRecarbrioMerck Sharp & Dohme B.V. (1)
- FinlandRecarbrioMerck Sharp & Dohme B.V.
- CzechiaRECARBRIOMerck Sharp & Dohme B.V., Haarlem
- United StatesRECARBRIOMerck Sharp & Dohme LLC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/12ac9cc3-51f9-4e8d-a12d-9073b5ba6f11 GET /v1/drugs/12ac9cc3-51f9-4e8d-a12d-9073b5ba6f11?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Recarbrio 500 mg - 500 mg - 250 mg",
"name_fr": "Recarbrio 500 mg - 500 mg - 250 mg",
"name_nl": "Recarbrio 500 mg - 500 mg - 250 mg",
"amp_code": "SAM554853-00",
"strengths": [
"250.0000",
"500.0000",
"500.0000",
"37.5000"
],
"pack_count": 1,
"substances": [
"Relebactam Monohydrate",
"Relebactam",
"Imipenem Monohydrate",
"Imipenem",
"Cilastatin Sodium",
"Cilastatin",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Imipenem, Cilastatin and Relebactam",
"authorisation_numbers": [
"EU/1/19/1420/001"
]
}See everything about imipenem, cilastatin and relebactam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.